The author is a Forbes contributor. The opinions expressed are those of the writer.

Loading ...

Loading ...

This story appears in the {{article.article.magazine.pretty_date}} issue of {{article.article.magazine.pubName}}. Subscribe

A study of analyst recommendations at the major brokerages shows that Inc (NYSE: PFE) is the #1 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Pfizer Inc is also a top tier analyst pick among the broader S&P 500 index components, claiming the #15 spot out of 500.

In forming this rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages. Investors often interpret analyst opinions from different angles — a popular analyst pick could mean that many sharp minds individually came to the same bullish conclusion, and therefore the stock should do well, but it could also mean that if the company stumbles, that would come as a negative surprise. Click here to find out The Top 15 Broker Darlings of the Dow: Current Top Analyst Picks »

From the other direction, when companies have a low rank among analysts, it isn't necessarily the case that investors should conclude that the stock will perform poorly. It can, of course, but a bullish investor could also take the contrarian angle and read into the data that there is lots of room for upside because the stock is so out of favor.

PFE operates in the Drugs & Pharmaceuticals sector, among companies like (JNJ) which is up about 0.2% today, and (NVS) trading higher by about 0.8%. Below is a three month price history chart comparing the stock performance of PFE, versus JNJ and NVS.